Scientists test new pill to fight deadly brain tumors
NCT ID NCT03107780
Summary
This early-stage study tested a new oral drug called navtemadlin (AMG 232) for glioblastoma, a fast-growing brain cancer. The trial had two parts: first, to see if the drug could reach brain tumor tissue in patients whose cancer had returned; second, to find a safe dose to combine with standard radiation for newly diagnosed patients. The study was terminated early and involved 32 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
-
UPMC-Shadyside Hospital
Pittsburgh, Pennsylvania, 15232, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.